Immuneering to Present Key Survival Data in Pancreatic Cancer
NEW YORK, Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company dedicated to enhancing the lives of cancer patients, is gearing up to reveal crucial overall survival and safety data from their Phase 2a clinical trial involving atebimetinib and mGnP. This trial focuses on first-line treatment in pancreatic cancer patients. A noteworthy aspect of this trial involves a median follow-up period of nine months with 34 participants.
Details of the Upcoming Conference Call
The company will host a conference call and live webcast on September 29, 2025, at 8:30 am ET. This event aims to elaborate on the promising results unveiled earlier. CEO Ben Zeskind expressed enthusiasm for this occasion, stating, "These exciting results underscore our commitment to providing the cancer community with essential insights into our findings." Immuneering aims to facilitate multiple platforms for engagement and understanding regarding these remarkable outcomes.
How to Join the Conference Call
Interested parties can listen to the live call by accessing the company’s conference link or by dialing into the respective phone numbers provided for different locations. For those in the U.S., the number to dial is (800) 715-9871, and for international participants, the number is (646) 307-1963. Ensure you reference conference ID 9502940 for proper identification.
Availability of Webcast Replay
A recording of the call will be made available shortly in the ‘Investors’ section of Immuneering’s official website. This allows stakeholders and interested individuals to revisit the discussion and explore the results in detail.
About Immuneering Corporation
Immuneering is devoted to advancing an entirely new class of cancer therapies known as Deep Cyclic Inhibitors. Their flagship product, atebimetinib, represents a significant evolution in cancer treatment. Designed for oral, once-daily intake, atebimetinib is specifically aimed at enhancing patient tolerance and treatment durabilities while targeting tumors driven by the MAPK pathway commonly found in pancreatic cancer and other solid tumors.
Current Focus and Development Pipeline
As part of their research endeavors, Immuneering is actively involved in conducting trials that not only assess the efficacy of atebimetinib but also explore its applicability in various advanced solid tumor treatments. There are additional early-stage programs in the company’s development pipeline that demonstrate the potential for broader applications in oncology.
Connecting with Immuneering
For a more comprehensive understanding of their clinical strategies and ongoing studies, you can visit Immuneering’s website. The dedicated team is committed to advancing cancer care through innovative research and development.
Media and Investor Contacts
Media Contact:
Carson Creehan
817-412-1096
carson.creehan@padillaco.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com
Frequently Asked Questions
What is the main focus of Immuneering Corporation?
Immuneering Corporation is focused on developing innovative cancer therapies, particularly targeting patients with solid tumors.
What type of cancer is the ongoing Phase 2a trial addressing?
The trial is addressing first-line pancreatic cancer patients, combining atebimetinib with mGnP.
When will the new data be presented?
The new overall survival and safety data will be presented on September 29, at 8:30 am ET during a conference call.
How can interested individuals participate in the conference call?
Individuals can participate by accessing the provided conference link or by dialing in to the relevant phone lines.
Where can I find more information about Immuneering's treatments?
More information can be found on Immuneering’s official website, where detailed insights into their clinical programs are available.
